EXOSMART®

Autologous plasma concentration, in your practice

Exosmart® is a sterile single-use Class IIa medical device, CE marked, manufactured by Medica S.p.A. (Italy). Its selective ultrafiltration technology concentrates the patient’s autologous plasma: plasma proteins, extracellular vesicles including exosomes, and other blood components.

The final preparation contains up to 30 × 10¹² particles/mL (range 5 to 30 × 10¹², measured by nanoparticle tracking analysis).

The preparation is performed on site, in the practice. The field of application is chosen by the physician, in accordance with the manufacturer’s instructions for use.

CE-marked medical device

Why EXOSMART®?

Autologous. Concentrated. In your practice.

exosmart® was designed for medical practice: an autologous preparation, produced on site from the patient’s own blood.

100%
Autologous

Prepared exclusively from the patient’s own blood, with no donor-derived material.

Concentrated preparation

Ultrafiltration concentrates the extracellular vesicles and proteins of the patient’s plasma.

Streamlined
Workflow

Designed for use in the practice or clinic, from blood draw to the final concentrate.

The Science

What Are Autologous Exosomes?

Exosomes are nanoscale extracellular vesicles, typically ranging from 30 to 150 nanometers in diameter. They are secreted by virtually all cell types and are abundantly present in peripheral blood. They take part in communication between cells and carry proteins, lipids and nucleic acids.

The scientific literature associates extracellular vesicles with tissue repair processes such as cell proliferation, angiogenesis and extracellular matrix remodelling. Prepared from the patient’s own blood, they introduce no donor-derived biological material.

exosmart® concentrates the extracellular vesicles and other components of the patient’s plasma, for immediate use in the practice.

Key Biological Properties

Intercellular Signaling

Carry proteins, lipids and nucleic acids between cells

Literature data

Associated in the literature with cell proliferation, differentiation and angiogenesis

Autologous origin

Prepared from the patient’s own blood, with no donor-derived material

Dimensions and biological role

Exosomes generally have a diameter between 30 and 150 nm. Despite their very small size, they take part in communication between cells.

Field of application

exosmart® is a preparation device: it concentrates the patient’s autologous plasma. The choice of field of application and route of administration rests solely with the physician, in accordance with the manufacturer’s instructions for use (IFU-PRT-EXOQJ-01, rev. 08).

EXOSMART® Concept

After centrifugation of the patient’s blood, the plasma contains extracellular vesicles, including exosomes, as well as proteins and other blood components.

exosmart® processes this plasma by ultrafiltration to concentrate these components.

The technology is based on an ultrafiltration membrane with a nominal molecular weight cut-off of approximately 15 kDa and an average pore diameter of less than 5 nm. Water and small free solutes cross the membrane, while extracellular vesicles, larger proteins and cells are retained and concentrated. Passage of an individual mediator also depends on how it is carried in plasma.

Under the pressure generated by the syringes, the plasma flows through the fibers of the exosmart® system. At the end of the procedure, the concentrate is recovered in the syringe.

The resulting concentrate is autologous: it is derived exclusively from the patient’s own blood.

Starting material:

Ultrafiltration technology

exosmart® was developed through the combination of a filtration technology based on capillary membranes and advanced blood product concentration techniques.

HIGHLY CONCENTRATED
Up to 30 × 10¹²
particles per mL (range 5 to 30 × 10¹²)

With selective ultrafiltration, water and small solutes are removed into the collection bag, while extracellular vesicles, larger proteins and cells are retained within the system’s fibers.

Nanoporous fibers: nominal cut-off of approximately 15 kDa, average pore diameter of less than 5 nm.

Protocol

How It Works

The exosmart® protocol fits into your existing clinical environment. Three steps turn a venous blood draw into an autologous preparation specific to each patient.

The procedure is performed in the practice or clinic, with the equipment and steps described in the manufacturer’s instructions for use.

Blood
Collection
Plasma
concentration
Application
by the physician

Why Partner with exosmart® ?

Availability

exosmart® is available in Switzerland to qualified healthcare professionals.

Differentiate Your Practice

Offer an autologous preparation, produced from each patient’s own blood.

Expand Your Protocol Portfolio

Complement your existing offering with an autologous preparation performed in the practice.

Clinical & Commercial Support

Access dedicated training, clinical protocols, and ongoing scientific support from the exosmart® team

Built for Modern Practices

A procedure performed in the practice that fits your clinic’s organization.

exosmart® is a CE-marked Class IIa medical device. For qualified healthcare professionals only. To be used in accordance with the manufacturer’s instructions for use.

Bring exosmart® to your practice

Contact our team for a presentation or an in-practice demonstration.

Scroll to Top